Document is current
Any future updates will be listed below
-
Authors
Riesmeijer, Sophie A. https://orcid.org/0000-0001-9196-7361
Kamali, Zoha https://orcid.org/0000-0001-6492-5887
Ng, Michael https://orcid.org/0000-0003-3463-5568
Drichel, Dmitriy
Piersma, Bram
Becker, Kerstin
Layton, Thomas B.
Nanchahal, Jagdeep https://orcid.org/0000-0002-9579-9411
Nothnagel, Michael https://orcid.org/0000-0001-8305-7114
Vaez, Ahmad https://orcid.org/0000-0001-9048-3795
Hennies, Hans Christian https://orcid.org/0000-0001-7210-2389
Werker, Paul M. N.
Furniss, Dominic https://orcid.org/0000-0003-2780-7173
Nolte, Ilja M. https://orcid.org/0000-0001-5047-4077
- License Information
-
More Information
Article History
Received: 7 June 2022
Accepted: 13 December 2023
First Online: 3 January 2024
Competing interests
: The authors have the following to disclose: P.W. was science and engineering research board (SERB) member for an industry sponsored study on collagenase of Fidia Ltd, Milan, Italy. J.N. consults for and holds equity in 180 Life Sciences, which has exclusively licensed IP from the University of Oxford on the use of anti-TNF for early-stage Dupuytren’s disease. All other authors declare no competing interests.
